What retatrutide is, and where its research currently stands
In short
Retatrutide is an investigational compound that acts on three receptors at once: GIP, GLP-1 and glucagon. It is the first triple agonist with published phase 2 data in people with obesity, where a mean weight reduction of 24.2% at 48 weeks was reported. It is not approved as a medicine in any country.
Retatrutide is a synthetic peptide designed to activate three different hormone receptors: GIP, GLP-1 and glucagon. That is what sets it apart from what came before. Semaglutide acts on one, tirzepatide on two, this one on three [1].
What has been published, and in whom
Unlike most compounds in this catalogue, the data here come from clinical trials in people, not animal models. That deserves spelling out: they were run under medical supervision, with pharmaceutical-grade product, inside an approved protocol.
- Obesity, phase 2. In a randomised placebo-controlled trial, mean weight reduction at 48 weeks reached 24.2% in the highest-dose group [1].
- Type 2 diabetes, phase 2. A separate trial across 42 US centres, with an active comparator as well as placebo, reported 16.9% weight reduction at 36 weeks alongside improvements in glycaemic control [2].
- Metabolic fatty liver disease, phase 2a. A third trial studied liver fat content [3].
A systematic review with meta-analysis later pooled the published randomised trials and their safety data [4].
Why three receptors and not one
The rationale the authors describe is that the three arms do different things: GLP-1 on satiety and insulin secretion, GIP on insulin sensitivity and fat tissue metabolism, glucagon on energy expenditure. The hypothesis is that combining them adds effects that limit one another when pursued separately [1].
Regulatory status
Retatrutide is not approved as a medicine in any country. Neither the European Medicines Agency, nor the Spanish AEMPS, nor their US counterpart has authorised any indication. It is in phase 3 trials, the stage before applying for authorisation, and that application may or may not end in approval.
What is sold here is a reagent for in vitro research. This page describes published literature. It is not medical information, does not describe a therapeutic use, and does not replace any healthcare professional.
What to look at when comparing suppliers
For a compound still in clinical research, identity matters more than anywhere else, because there is no commercial reference to check it against. Three facts that should be published without having to ask:
- HPLC purity for the specific batch, not a product-level figure.
- Identity confirmation by mass spectrometry, which is what separates the compound from another of similar weight.
- The certificate for the batch you receive, readable before you buy.
References
- [1] Jastreboff A.M. et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. View source
- [2] Rosenstock J. et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised phase 2 trial. Lancet. PMID 37385280 View source
- [3] Sanyal A.J. et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. PMC11271400 View source
- [4] Efficacy and safety of retatrutide: a systematic review and meta-analysis of randomized controlled trials (2025). PMC12026077 View source
This page reports what has been published in the scientific literature about a research molecule. It is not medical information, it does not describe a therapeutic use, and it does not replace any healthcare professional. The product is sold strictly for in vitro research.
